TED Ted Baker Plc

    2 February 2005

       Tepnel Life Sciences PLC - Research and Development Collaboration       

    Tepnel Life Sciences PLC (`Tepnel') signs R&D agreement with Boehringer    
                                   Ingelheim                                   

Manchester, UK. 2 February 2005* Tepnel Life Sciences' (AIM: TED) wholly owned
subsidiary, Diaclone Research (`Diaclone' Besan�on, France) announces today the
signing of a comprehensive research collaboration with Boehringer Ingelheim
(Ingelheim, Germany).

Under the terms of the agreement Diaclone will generate murine monoclonal
antibodies that recognise human immune regulatory cells. These antibodies will
be evaluated by Boehringer Ingelheim as research tools and possible antibody
therapeutics in main indication areas. The terms of the collaboration allow
Tepnel to market for research and diagnostic applications those monoclonal
antibodies generated by Diaclone which are not developed for therapeutic
indications by Boehringer Ingelheim.

Diaclone was recently acquired by Tepnel Life Sciences plc on December 14, 2004
and specialises in the development of monoclonal antibodies against
immunoregulatory cells and cellular secretion. Diaclone has developed more than
two thousand monoclonal antibodies against immunoregulatory cells and is a
leader in human cytokine research.

Ben Matzilevich, Tepnel's Chief Executive Officer, commented that, "The
acquisition of Diaclone was an important component of Tepnel's strategy of
penetrating both the research product and molecular diagnostic markets.
Tepnel's long term strategy is to focus on these two key growth markets
incorporating our DNA purification and analysis capabilities to enhance and
complement these product lines. Tepnel will continue to further expand into
these target markets with additional pharmaceutical agreements, M&A and organic
growth"

For Further Information:

Tepnel Life Sciences plc

Ben Matzilevich, CEO

Gron Ffoulkes-Davies, Finance Director

0161 946 2200

Seymour Pierce

Mark Percy, Corporate Finance

0207 107 8000

Boehringer Ingelheim

Ute Schmidt

External Communications

+49 6132 7797296

+49 6132 776601

De Facto Communications

Helena Podd

020 7940 1000

Notes to Editors

About Tepnel Life Sciences plc

Tepnel is a UK-based international life sciences instrumentation and services
company with a `tri-polar' strategy focused on providing the biomedical
industry with high-throughput automated DNA purification systems, manual DNA
purification kits and reagents, as well as scientific services for nucleic acid
purification, drug analysis, genotyping and genetically modified foods. Tepnel
was founded in 1992 to exploit DNA technology generated at UMIST (University of
Manchester Institute of Science and Technology) and is quoted on the AIM
segment of the London Stock Exchange (AIM: TED). More information on Tepnel can
be found at www.tepnel.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany, it operates globally with 152
affiliates in 45 countries and more than 34,000 employees. Since it was founded
in 1885, the family-owned company has been committed to researching,
developing, manufacturing and marketing novel products of high therapeutic
value for human and veterinary medicine. In 2003, Boehringer Ingelheim posted
net sales of 7.4 billion euro while spending more than one fifth of net sales
in its largest business segment, Prescription Medicines, on research and
development. For more information please visit www.boehringer-ingelheim.com



END

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024